Healthcare / BiotechnologyNasdaqCM
$5.47
-0.41 (-6.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-21.3M · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$62M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-34.1%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
-38.6%
FCF CAGR
—
FCF margin
-5980.5%
FCF / Net income
1.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $800000.0 · net income $-45.3M · FCF $-47.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $800000.00 | $800000.00 | $3.5M | $8.0M | $15.6M | $31.0M | $9.2M |
| Net Income | $-45.3M | $-45.3M | $-36.6M | $-21.1M | $-68.8M | $-34.1M | $-44.3M |
| EBITDA | $-47.4M | $-47.4M | $-35.5M | $-18.8M | — | — | — |
| EPS | -9.64 | -9.64 | -4.33 | -2.87 | -22.80 | -14.64 | — |
| Operating Margin | -6056.4% | -6056.4% | -1057.1% | -275.4% | -454.0% | -110.2% | -484.2% |
| Net Margin | -5668.6% | -5668.6% | -1044.8% | -265.6% | -440.3% | -110.1% | -481.4% |
| Balance Sheet | |||||||
| Debt/Equity | 0.02 | 0.02 | -0.05 | -0.01 | — | — | — |
| Current Ratio | 18.39 | 18.39 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-47.8M | $-47.8M | $-21.3M | $-18.5M | $-75.5M | $-62.0M | $-38.6M |
| Returns | |||||||
| ROE | -34.1% | -34.1% | 22.8% | 16.8% | -46.8% | -16.4% | 43.8% |
| Valuation | |||||||
| P/B | 0.20 | 0.20 | — | — | — | — | — |
| Growth & Yield | |||||||
| Revenue Growth | -77.1% | -77.1% | -56.0% | — | -49.6% | 237.0% | — |
| EPS Growth | -122.8% | -122.8% | -51.0% | — | -55.7% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-61.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.33 → -9.64
Residual
-61.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.